184 related articles for article (PubMed ID: 17450466)
1. Humoral immune response to MUC1 and to the Thomsen-Friedenreich (TF) glycotope in patients with gastric cancer: relation to survival.
Kurtenkov O; Klaamas K; Mensdorff-Pouilly S; Miljukhina L; Shljapnikova L; Chuzmarov V
Acta Oncol; 2007; 46(3):316-23. PubMed ID: 17450466
[TBL] [Abstract][Full Text] [Related]
2. Impact of Helicobacter pylori infection on the humoral immune response to MUC1 peptide in patients with chronic gastric diseases and gastric cancer.
Klaamas K; Kurtenkov O; von Mensdorff-Pouilly S; Shljapnikova L; Miljukhina L; Brjalin V; Lipping A
Immunol Invest; 2007; 36(4):371-86. PubMed ID: 17691020
[TBL] [Abstract][Full Text] [Related]
3. Aberrant glycosylation of the anti-Thomsen-Friedenreich glycotope immunoglobulin G in gastric cancer patients.
Kodar K; Izotova J; Klaamas K; Sergeyev B; Järvekülg L; Kurtenkov O
World J Gastroenterol; 2013 Jun; 19(23):3573-82. PubMed ID: 23801858
[TBL] [Abstract][Full Text] [Related]
4. The Thomsen-Friedenreich antigen and alphaGal-specific human IgG glycoforms: concanavalin A reactivity and relation to survival of cancer patients.
Kodar K; Kurtenkov O; Klaamas K
Immunol Invest; 2009; 38(8):704-17. PubMed ID: 19860583
[TBL] [Abstract][Full Text] [Related]
5. Hidden IgG Antibodies to the Tumor-Associated Thomsen-Friedenreich Antigen in Gastric Cancer Patients: Lectin Reactivity, Avidity, and Clinical Relevance.
Kurtenkov O; Klaamas K
Biomed Res Int; 2017; 2017():6097647. PubMed ID: 28316982
[TBL] [Abstract][Full Text] [Related]
6. Immunoreactivity of monoclonal antibody BW835 represents a marker of progression and prognosis in early gastric cancer.
Baldus SE; Zirbes TK; Glossmann J; Fromm S; Hanisch FG; Mönig SP; Schröder W; Schneider PM; Flucke U; Karsten U; Thiele J; Hölscher AH; Dienes HP
Oncology; 2001; 61(2):147-55. PubMed ID: 11528254
[TBL] [Abstract][Full Text] [Related]
7. Postoperative change of anti-Thomsen-Friedenreich and Tn IgG level: the follow-up study of gastrointestinal cancer patients.
Smorodin EP; Kurtenkov OA; Sergeyev BL; Kodar KE; Chuzmarov VI; Afanasyev VP
World J Gastroenterol; 2008 Jul; 14(27):4352-8. PubMed ID: 18666325
[TBL] [Abstract][Full Text] [Related]
8. MUC1 expression and anti-MUC1 serum immune response in head and neck squamous cell carcinoma (HNSCC): a multivariate analysis.
Rabassa ME; Croce MV; Pereyra A; Segal-Eiras A
BMC Cancer; 2006 Oct; 6():253. PubMed ID: 17064405
[TBL] [Abstract][Full Text] [Related]
9. Systemic humoral anti-Helicobacter pylori immune response in patients with gastric malignancies and benign gastroduodenal disease.
Manojlovic N; Nikolic L; Pilcevic D; Josifovski J; Babic D
Hepatogastroenterology; 2004; 51(55):282-4. PubMed ID: 15011886
[TBL] [Abstract][Full Text] [Related]
10. Association of Helicobacter pylori gastric infection with the suppressed Thomsen-Friedenreich antigen natural humoral response.
Kurtenkov O; Wadström T; Klaamas K; Vorobjova T; Uibo R
Scand J Gastroenterol; 1995 Feb; 30(2):116-21. PubMed ID: 7732332
[TBL] [Abstract][Full Text] [Related]
11. Antibodies reactive with the protein core of MUC1 mucin are present in ovarian cancer patients and healthy women.
Richards ER; Devine PL; Quin RJ; Fontenot JD; Ward BG; McGuckin MA
Cancer Immunol Immunother; 1998 Jul; 46(5):245-52. PubMed ID: 9690452
[TBL] [Abstract][Full Text] [Related]
12. Increased sialylation of anti-Thomsen-Friedenreich antigen (CD176) antibodies in patients with gastric cancer: a diagnostic and prognostic potential.
Kurtenkov O; Izotova J; Klaamas K; Sergeyev B
Biomed Res Int; 2014; 2014():830847. PubMed ID: 25276822
[TBL] [Abstract][Full Text] [Related]
13. Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin.
von Mensdorff-Pouilly S; Verstraeten AA; Kenemans P; Snijdewint FG; Kok A; Van Kamp GJ; Paul MA; Van Diest PJ; Meijer S; Hilgers J
J Clin Oncol; 2000 Feb; 18(3):574-83. PubMed ID: 10653872
[TBL] [Abstract][Full Text] [Related]
14. Circulating anti-MUC1 IgG antibodies as a favorable prognostic factor for pancreatic cancer.
Hamanaka Y; Suehiro Y; Fukui M; Shikichi K; Imai K; Hinoda Y
Int J Cancer; 2003 Jan; 103(1):97-100. PubMed ID: 12455059
[TBL] [Abstract][Full Text] [Related]
15. Tissue and serum MUC1 mucin detection in breast cancer patients.
Croce MV; Isla-Larrain MT; Demichelis SO; Gori JR; Price MR; Segal-Eiras A
Breast Cancer Res Treat; 2003 Oct; 81(3):195-207. PubMed ID: 14620915
[TBL] [Abstract][Full Text] [Related]
16. Natural IgM and IgG antibodies to Thomsen-Friedenreich (T) antigen in serum of patients with gastric cancer and blood donors--relation to Lewis (a,b) histo-blood group phenotype.
Kurtenkov O; Miljukhina L; Smorodin J; Klaamas K; Bovin N; Ellamaa M; Chuzmarov V
Acta Oncol; 1999; 38(7):939-43. PubMed ID: 10606423
[TBL] [Abstract][Full Text] [Related]
17. Signatures of anti-Thomsen - Friedenreich antigen antibody diversity in colon cancer patients.
Kurtenkov O; Bubina M; Klaamas K
Exp Oncol; 2018 Mar; 40(1):48-58. PubMed ID: 29600973
[TBL] [Abstract][Full Text] [Related]
18. The relation of the level of serum anti-TF, -Tn and -alpha-Gal IgG to survival in gastrointestinal cancer patients.
Smorodin E; Sergeyev B; Klaamas K; Chuzmarov V; Kurtenkov O
Int J Med Sci; 2013; 10(12):1674-82. PubMed ID: 24151439
[TBL] [Abstract][Full Text] [Related]
19. Coexpression of MUC1 mucin peptide core and the Thomsen-Friedenreich antigen in colorectal neoplasms.
Baldus SE; Hanisch FG; Kotlarek GM; Zirbes TK; Thiele J; Isenberg J; Karsten UR; Devine PL; Dienes HP
Cancer; 1998 Mar; 82(6):1019-27. PubMed ID: 9506345
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the anti-Thomsen-Friedenreich antibodies Nemod-TF1 and Nemod-TF2 as prognostic markers in breast cancer.
Heublein S; Egger M; Zhu J; Berger L; Mayr D; Schindlbeck C; Kuhn C; Hofmann SS; Schuetz F; Jeschke U; Ditsch N
Breast Cancer Res Treat; 2020 Feb; 179(3):643-652. PubMed ID: 31828591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
